1R. McLaughlin,D. O’Hanlon,M. Kerin,P. Kenny,H. Grimes,H. F. Given.Are elevated levels of the tumour marker CA19-9 of any clinical significance? — An evaluation[J].Irish Journal of Medical Science.1999(2)
2Aoki D,Nomata K,Kanda S,et al.A case of pyonephrosis caused by ureteral stones with elevated serum levels of CA19-9[].Hinyokika Kiyo.1999
3Fouad M,Khallaf E.CA19-9 in carcinoma of the bilharzial bladder[].Journal of the Royal College of Surgeons of Edinburgh.1994
4Mansuri OA.Urinary CA19-9 as a marker for bladder cancer[].The Lancet.1995
5Tizzani A,Cassetta G,Cicigoi A,et al.Tumor markers (CEA, TPA and CA 19-9) in urine of bladder cancer patients[].International Journal of Biological Markers.1987
2Martin B ,Tatiana B ,Ahmad S ,et al. Current concepts in biomarker technology for bladder cancers [ J ]. Clin Chem,2000,46 (5) :595.
3Messing EM. Urothelial tumors of the urinary tract [ M ]. Campbell' s urology. 8th ed. Philadelphia ( PA ) : W. B.Saunders ,2002:2732 - 2784.
4Jalil H, Ali RG, Mohammad MM, et al. Detection of recurrent bladder cancer NMP22 test or urine cytology [ J]. J Urol,2012, 9(1) :367 -372.
5Burke DM, Shaekley DC, O' Reilly PH. The community-based morbidity of flexible cystoscopy [ J ]. BJU Int,2002,89 (4) : 347 - 349.
6Berezney R. The nuelear matrix : a heuristic model for investig- ating genomic organization and function in the cell nucleus [ J ]. J Cell Bioehem, 1991,47 (2) : 109 - 123.
8Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear matrix proteins for cancer diagnosis [ J ]. CRC Crit Rev Eukaryotic Gene Expr, 1996,6 ( 2 - 3 ) : 189 - 214.
9Carpinito GA,Stadler WM, Briggman JV, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract[ J ]. J Urol, 1996,156 (4) : 1280 - 1285.
10Ponsky LE, Sharma S,Pandrangi L,et al. Screening and monitoring for bladder cancer:refining the use of NMP22[ J]. J Urol,2O01,166 (1) :75 -78.
